Loading…
Chandra Bhagat Pharma (BSE 542934)₹57.85+4.23%Pharmaceuticals
In the Mar 2026 quarter (standalone), Chandra Bhagat Pharma reported sales of ₹91.07 Cr, up 313.6% from Mar 2025, and net profit of ₹2.99 Cr. For the year to Mar 2026, sales were ₹116 Cr and net profit ₹2.99 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 74.98 | 119 | 102 | 65.04 | 22.02 | 26.02 | 91.07 |
| Expenses | 73.94 | 124 | 104 | 65.92 | 21.96 | 23.98 | 88.92 |
| Operating Profit | 2.01 | −5.01 | −2.01 | −1.01 | 0.00 | 2.01 | 2.01 |
| OPM % | 2.4% | −4.2% | −2.0% | −1.8% | −1.2% | 7.1% | 2.4% |
| Other Income | 0.00 | 7.03 | 4.01 | 3.01 | 2.01 | 0.00 | 3.01 |
| Interest | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.00 |
| Profit before tax | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 3.99 |
| Tax % | 14.9% | 31.9% | 33.9% | −11.1% | 68.9% | 22.0% | 25.9% |
| Net Profit | 0.99 | 0.99 | 0.99 | 0.99 | 0.00 | 0.00 | 2.99 |
| EPS (Rs) | 0.73 | 0.84 | 1.20 | 0.91 | 0.24 | 0.61 | 3.46 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 61.03 | 79.99 | 89.95 | 96.99 | 106 | 94.06 | 70.99 | 94.01 | 120 | 221 | 89.07 | 116 |
| Expenses | 57.96 | 75.90 | 84.87 | 91.86 | 102 | 90.90 | 66.92 | 90.86 | 116 | 228 | 87.84 | 112 |
| Operating Profit | 3.01 | 3.01 | 4.01 | 5.01 | 5.01 | 3.01 | 4.01 | 3.01 | 3.01 | −7.01 | 1.01 | 4.01 |
| OPM % | 4.9% | 4.3% | 4.9% | 4.7% | 4.3% | 3.3% | 5.0% | 3.0% | 2.8% | −3.2% | 0.7% | 3.3% |
| Other Income | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 2.01 | 0.00 | 11.03 | 3.01 | 3.01 |
| Interest | 1.99 | 2.99 | 3.98 | 3.98 | 3.98 | 2.99 | 3.98 | 2.99 | 1.99 | 0.99 | 1.99 | 1.99 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 |
| Profit before tax | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 0.00 | 0.00 | 0.99 | 0.99 | 1.99 | 0.99 | 3.99 |
| Tax % | 38.9% | 50.9% | 27.0% | 33.0% | 21.9% | 25.9% | 31.9% | 26.9% | 21.9% | 32.9% | 25.9% | 25.9% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 0.00 | 0.00 | 0.99 | 0.99 | 1.99 | 0.99 | 2.99 |
| EPS (Rs) | 10.30 | 8.38 | 15.80 | 24.65 | 10.30 | 0.42 | 0.26 | 1.07 | 1.22 | 2.04 | 1.15 | 4.05 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.41 | 0.41 | 0.41 | 0.41 | 0.66 | 7.98 | 7.97 | 8.00 | 8.02 | 7.99 | 7.98 | 7.98 |
| Reserves | 5.99 | 5.99 | 6.99 | 7.99 | 13.99 | 17.99 | 18.01 | 19.02 | 20.06 | 20.98 | 21.99 | 26.01 |
| Borrowings | 28.12 | 28.09 | 22.09 | 22.09 | 31.14 | 30.09 | 27.10 | 21.09 | 19.08 | 16.06 | 21.09 | 17.07 |
| Other Liabilities | 8.01 | 10.05 | 26.10 | 28.08 | 37.13 | 19.10 | 19.08 | 25.12 | 14.07 | 56.27 | 51.19 | 45.19 |
| Total Liabilities | 42.11 | 44.12 | 56.17 | 58.15 | 83.25 | 75.16 | 72.16 | 72.23 | 61.23 | 102 | 102 | 94.25 |
| Fixed Assets | 1.01 | 1.01 | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 3.01 | 3.01 | 3.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 4.99 | 0.99 | 3.99 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 |
| Other Assets | 41.10 | 44.11 | 51.17 | 56.15 | 78.26 | 74.17 | 71.16 | 72.23 | 60.22 | 99.29 | 99.24 | 90.25 |
| Inventories | 22.01 | 21.01 | 27.01 | 32.99 | 43.95 | 43.99 | 34.97 | 33.97 | 28.98 | 8.99 | 0.99 | 5.01 |
| Trade receivables | 12.01 | 14.02 | 20.03 | 18.02 | 26.05 | 14.03 | 15.02 | 15.03 | 8.02 | 39.07 | 36.03 | 55.12 |
| Cash & equivalents | 4.99 | 4.99 | 0.99 | 0.99 | 0.00 | 0.00 | 2.99 | 5.99 | 5.99 | 4.99 | 0.99 | 2.99 |
| Total Assets | 42.11 | 44.12 | 56.17 | 58.15 | 83.25 | 75.16 | 72.16 | 72.23 | 61.23 | 102 | 102 | 94.25 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −8.98 | −5.98 | 3.99 | −6.98 | 7.97 | 11.97 | 4.98 | 5.98 | −5.98 | 8.98 |
| Cash from investing activity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −2.01 | −1.01 | 0.00 |
| Cash from financing activity | 7.98 | 6.99 | −3.99 | 6.98 | −5.99 | −9.99 | −3.99 | −5.99 | 1.99 | −5.99 |
| Net cash flow | −0.99 | 0.00 | 0.00 | 0.00 | 1.99 | 2.99 | 0.99 | −0.99 | −3.99 | 1.99 |
| Capex | 0.00 | 0.03 | 0.02 | 0.00 | 0.01 | 0.09 | 0.36 | 2.27 | 1.19 | 0.91 |
| Free cash flow | −8.99 | −5.99 | 3.99 | −6.99 | 8.01 | 11.99 | 4.99 | 3.99 | −6.01 | 7.99 |
| CFO / OP % | −200.0% | −129.0% | 98.0% | −238.0% | 229.0% | 440.0% | 164.0% | −94.0% | −805.0% | 250.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 72 | 67 | 81 | 68 | 91 | 55 | 81 | 59 | 26 | 66 | 149 | 172 |
| Inventory days | 178 | 124 | 134 | 146 | 175 | 188 | 216 | 154 | 101 | 16 | 4 | 19 |
| Days payable | 43 | 33 | 81 | 69 | 117 | 53 | 79 | 12 | 11 | 23 | 45 | 124 |
| Cash conversion cycle | 205 | 156 | 132 | 143 | 146 | 188 | 216 | 199 | 114 | 57 | 107 | 65 |
| Working capital days | 166 | 134 | 125 | 138 | 83 | 148 | 177 | 104 | 75 | 36 | 101 | 77 |
| ROCE % | 10.1% | 10.1% | 15.1% | 17.1% | 13.1% | 7.1% | 7.0% | 9.1% | 7.0% | 8.1% | 6.0% | 12.1% |
For the Mar 2026 quarter, Chandra Bhagat Pharma reported sales of ₹91.07 Cr, up 313.6% year on year and net profit of ₹2.99 Cr. The operating margin was 2.4%.
Chandra Bhagat Pharma's sales for the year to Mar 2026 were ₹116 Cr.
Net profit for the year to Mar 2026 was ₹2.99 Cr. Earnings per share over the same trailing period were ₹4.05.
Chandra Bhagat Pharma reported borrowings of ₹17.07 Cr at Mar 2026, against cash and equivalents of ₹2.99 Cr.
Cash from operations was ₹8.98 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹7.99 Cr.